- Advanced equipment and technique
- Experienced scientific team
- Highly reliable and reproducible result
- Data analysis, detailed report with results and discussion
- Quality one-stop service

Abemaciclib - CAS 1231929-97-7

Inquiry

Catalog Number	Size	Price	Stock	Quantity
BP-300081	100 mg	$197	In stock

Add to cart

Abemaciclib is an orally available cyclin-dependent kinase (CDK) inhibitor that targets the CDK4 (cyclin D1) and CDK6 (cyclin D3) cell cycle pathway, with potential antineoplastic activity. It is used for the treatment of advanced or metastatic breast cancers.

* Please be kindly noted that our services and products can only be used for research to organizations or companies and not intended for any clinical or individuals.

Molecular Formula

C27H32F2N8

Molecular Weight

506.61

Abemaciclib

- Specification
  - Related CAS
    
    1231930-82-7 (mesylate)
    
    Purity
    
    ≥98%
    
    Appearance
    
    Light Yellow Solid
    
    IUPAC Name
    
    N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine
    
    Synonyms
    
    LY-2835219; LY 2835219; LY2835219; Verzenio; N-[5-[(4-ethylpiperazin-1-yl)methyl]pyridin-2-yl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine
- Properties
  - Melting Point
    
    175-178°C
    
    InChI Key
    
    UZWDCWONPYILKI-UHFFFAOYSA-N
    
    InChI
    
    InChI=1S/C27H32F2N8/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34)
    
    Canonical SMILES
    
    CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F
- Reference Reading
  - 1.Optimising the combination dosing strategy of abemaciclib and vemurafenib in BRAF-mutated melanoma xenograft tumours.
    Tate SC1, Burke TF2, Hartman D2, Kulanthaivel P2, Beckmann RP2, Cronier DM1. Br J Cancer. 2016 Mar 15;114(6):669-79. doi: 10.1038/bjc.2016.40.
    BACKGROUND: Resistance to BRAF inhibition is a major cause of treatment failure for BRAF-mutated metastatic melanoma patients. Abemaciclib, a cyclin-dependent kinase 4 and 6 inhibitor, overcomes this resistance in xenograft tumours and offers a promising drug combination. The present work aims to characterise the quantitative pharmacology of the abemaciclib/vemurafenib combination using a semimechanistic pharmacokinetic/pharmacodynamic modelling approach and to identify an optimum dosing regimen for potential clinical evaluation.
- Preparing Stock Solutions
  - ConcentrationVolumeMass 1 mg 5 mg 10 mg
    
    1 mM 1.9740 mL 9.8699 mL 19.7398 mL
    
    5 mM 0.3948 mL 1.9740 mL 3.9480 mL
    
    10 mM 0.1974 mL 0.9870 mL 1.9740 mL
    
    50 mM - - -

ConcentrationVolumeMass	1 mg	5 mg	10 mg
1 mM	1.9740 mL	9.8699 mL	19.7398 mL
5 mM	0.3948 mL	1.9740 mL	3.9480 mL
10 mM	0.1974 mL	0.9870 mL	1.9740 mL
50 mM	-	-	-

Bio Calculators

Stock concentration: *

Desired final volume: *

Desired concentration: *

* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C₁V₁ = C₂V₂

Calculate

* Total Molecular Weight:

g/mol

Tip: Chemical formula is case sensitive. C22H30N4O √ c22h30n40 ╳

Formula weight: *

g/mol

Desired final volume: *

Desired concentration: *